_Drug development processes are tremendously inefficient. Developing a new drug can take up to fifteen years fr...
_Drug development processes are tremendously inefficient. Developing a new drug can take up to fifteen years from the patent until it reaches the patient and can cost up to a billion dollars_, he says
As a Clinical Pharmacologist and Epidemiologist Dr. Romero has focused on understanding and analyzing the process starting from discovery of new cells, passing through the drug development stage and reaching clinical administration.
He became interested in Alzheimer_s because many people he knows have been touched by this disease in one way or the other. Given the current increased life expectancy, the likelihood of at least one person of each family falling victim to Alzheimer_s is high.
_Contributing to increase efficiency for Alzheimer_s drug development processes through pharmacometric models is something which I have been devoted and that I find deeply gratifying_, says the expert.
The task of pharmacometrics
Pharmacometrics is the science which involves pharmacology, physiopathology, statistics and clinics with the purpose of developing quantitative models which describe and forecast the interaction between the patient and drug use.
_The vision of a drug development process based on mathematical models could be a reality in the near future. This would reduce costs and time to provide access to new drugs_, says Romero.
Romero works with these models as Director of the Critical Path Institute, a unique organization which provides a neutral infrastructure for people involved in these processes (industry, regulating agencies, patient groups and academia) and share non-competitive information in order to expedite drug development processes.
Meanwhile the Coalition Against Major Disease Pharmacometrics Group which developed a model based on integrating nine Alzheimer_s patient clinical studies has published 72 scientific articles on the subject matter and worked with data from the Alzheimer_s Disease Neuroimaging Initiative.
_The capability of the model to simulate countless clinical tests will allow scientists from the pharmaceutical industry, academic institutions and regulating agencies, to choose the design of the clinical study which offers the greatest reliability to assess the efficiency of the new Alzheimer_s disease treatments_, says Romero.
The model determines that it is a priority to discover an effective treatment for this disease which given its high costs and increasing trend within the population could make health systems around the world go bankrupt.
The specific model is part of the Dr. Romero_s lecture which will be provided during UNal Medicine Faculty_s and UNal Medicine Alumni Association_s 16th Conference on Basic Sciences and Clinical Specialties.
The congress which will be held between September 18 and 20 will include nine Colombian physicians, besides Dr. Romero, which live abroad and will provide their knowledge and experience on relevant topics for world population health.
Agencia de Noticias UN